NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 194)
Posted On: 11/25/2019 4:34:30 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its recent receipt of notification (the “Notification Letter on Compliance”) from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the “Nasdaq”) that indicates Predictive Oncology has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”). Per the update, Predictive Oncology received, on November 16, 2018, notification from the Nasdaq (the “Notification Letter on Deficiency”) indicating that the closing bid price per share had been below $1.00 for a period of 30 Consecutive business days and that the Company did not meet the Minimum Price Bid Requirement. The Notification Letter on Deficiency stated that if, at any time during the Compliance Period, the closing bid price per share is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. According to the Notification Letter on Compliance, Nasdaq staff has determined that for 10 consecutive business days, beginning October 29, 2019 through November 11, 2019, the closing bid price of POAI’s common stock has been at $1.00 per share or greater, and the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is now closed.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its recent receipt of notification (the “Notification Letter on Compliance”) from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the “Nasdaq”) that indicates Predictive Oncology has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”). Per the update, Predictive Oncology received, on November 16, 2018, notification from the Nasdaq (the “Notification Letter on Deficiency”) indicating that the closing bid price per share had been below $1.00 for a period of 30 Consecutive business days and that the Company did not meet the Minimum Price Bid Requirement. The Notification Letter on Deficiency stated that if, at any time during the Compliance Period, the closing bid price per share is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. According to the Notification Letter on Compliance, Nasdaq staff has determined that for 10 consecutive business days, beginning October 29, 2019 through November 11, 2019, the closing bid price of POAI’s common stock has been at $1.00 per share or greater, and the Company has regained compliance with the Minimum Bid Price Requirement, and the matter is now closed.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)